ERBB2 and Familial prostate cancer: c-Src, the most studied SFK, has been implicated in conferring resistance to many targeted therapies, such as anti-EGFR therapies in lung cancer,33 antiandrogen therapies in prostate cancer,34 as well as anti-HER2 therapies (trastuzumab)25 and antioestrogen therapies35 in breast cancer.